DE2454619A1 - Verfahren zur herstellung neuer heterocyclischer verbindungen - Google Patents
Verfahren zur herstellung neuer heterocyclischer verbindungenInfo
- Publication number
 - DE2454619A1 DE2454619A1 DE19742454619 DE2454619A DE2454619A1 DE 2454619 A1 DE2454619 A1 DE 2454619A1 DE 19742454619 DE19742454619 DE 19742454619 DE 2454619 A DE2454619 A DE 2454619A DE 2454619 A1 DE2454619 A1 DE 2454619A1
 - Authority
 - DE
 - Germany
 - Prior art keywords
 - formula
 - compounds
 - dihydro
 - acid
 - addition salts
 - Prior art date
 - Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
 - Withdrawn
 
Links
- 238000000034 method Methods 0.000 title claims description 15
 - 150000002391 heterocyclic compounds Chemical class 0.000 title 1
 - 150000001875 compounds Chemical class 0.000 claims description 41
 - 239000002253 acid Substances 0.000 claims description 27
 - 150000003839 salts Chemical class 0.000 claims description 18
 - 125000000217 alkyl group Chemical group 0.000 claims description 7
 - 125000004432 carbon atom Chemical group C* 0.000 claims description 7
 - 238000002360 preparation method Methods 0.000 claims description 6
 - 229910052739 hydrogen Inorganic materials 0.000 claims description 2
 - 239000001257 hydrogen Substances 0.000 claims description 2
 - 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
 - 230000002378 acidificating effect Effects 0.000 claims 2
 - 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
 - YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
 - OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
 - ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
 - WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
 - HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
 - 239000000243 solution Substances 0.000 description 7
 - LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
 - JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
 - 238000006243 chemical reaction Methods 0.000 description 6
 - CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
 - 238000004519 manufacturing process Methods 0.000 description 5
 - CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
 - AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
 - ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
 - 150000001408 amides Chemical class 0.000 description 3
 - -1 for example Substances 0.000 description 3
 - 230000007062 hydrolysis Effects 0.000 description 3
 - 238000006460 hydrolysis reaction Methods 0.000 description 3
 - 238000002844 melting Methods 0.000 description 3
 - 230000008018 melting Effects 0.000 description 3
 - 239000003960 organic solvent Substances 0.000 description 3
 - UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
 - 235000011121 sodium hydroxide Nutrition 0.000 description 3
 - 239000007858 starting material Substances 0.000 description 3
 - XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
 - QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
 - HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
 - RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
 - IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
 - QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
 - WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
 - DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
 - 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
 - 230000002152 alkylating effect Effects 0.000 description 2
 - 230000029936 alkylation Effects 0.000 description 2
 - 238000005804 alkylation reaction Methods 0.000 description 2
 - 239000002585 base Substances 0.000 description 2
 - 239000003795 chemical substances by application Substances 0.000 description 2
 - 239000012320 chlorinating reagent Substances 0.000 description 2
 - 238000001816 cooling Methods 0.000 description 2
 - 230000017858 demethylation Effects 0.000 description 2
 - 238000010520 demethylation reaction Methods 0.000 description 2
 - CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 2
 - 239000003814 drug Substances 0.000 description 2
 - 238000001035 drying Methods 0.000 description 2
 - 230000000694 effects Effects 0.000 description 2
 - 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
 - 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
 - 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
 - 239000000203 mixture Substances 0.000 description 2
 - 239000003791 organic solvent mixture Substances 0.000 description 2
 - BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
 - 239000000047 product Substances 0.000 description 2
 - FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
 - SUXLVXOMPKZBOV-CXAGYDPISA-N (6ar,9r)-n,n-diethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](NC[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 SUXLVXOMPKZBOV-CXAGYDPISA-N 0.000 description 1
 - RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
 - NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
 - NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
 - VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
 - UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
 - YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
 - CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
 - PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
 - 229960000583 acetic acid Drugs 0.000 description 1
 - 150000007513 acids Chemical class 0.000 description 1
 - 239000002671 adjuvant Substances 0.000 description 1
 - 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
 - 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
 - 150000008064 anhydrides Chemical class 0.000 description 1
 - 150000001540 azides Chemical class 0.000 description 1
 - 239000011230 binding agent Substances 0.000 description 1
 - 230000036772 blood pressure Effects 0.000 description 1
 - 239000007853 buffer solution Substances 0.000 description 1
 - 238000009833 condensation Methods 0.000 description 1
 - 230000005494 condensation Effects 0.000 description 1
 - 238000006482 condensation reaction Methods 0.000 description 1
 - 239000013078 crystal Substances 0.000 description 1
 - 238000002425 crystallisation Methods 0.000 description 1
 - 230000008025 crystallization Effects 0.000 description 1
 - HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
 - 229960004704 dihydroergotamine Drugs 0.000 description 1
 - 239000002552 dosage form Substances 0.000 description 1
 - 229940079593 drug Drugs 0.000 description 1
 - 229960003133 ergot alkaloid Drugs 0.000 description 1
 - 150000002148 esters Chemical class 0.000 description 1
 - 210000003608 fece Anatomy 0.000 description 1
 - 238000001914 filtration Methods 0.000 description 1
 - 239000012362 glacial acetic acid Substances 0.000 description 1
 - 125000000623 heterocyclic group Chemical group 0.000 description 1
 - 230000003301 hydrolyzing effect Effects 0.000 description 1
 - 239000012442 inert solvent Substances 0.000 description 1
 - 239000000543 intermediate Substances 0.000 description 1
 - 238000002955 isolation Methods 0.000 description 1
 - 230000005923 long-lasting effect Effects 0.000 description 1
 - FSIZNIXUPRQTLZ-QMTHXVAHSA-N lysergic acid Chemical class C1=CC=C2C3=C[C@@H](C(O)=O)CN(C)[C@@H]3CC3=CN=C1[C]32 FSIZNIXUPRQTLZ-QMTHXVAHSA-N 0.000 description 1
 - 229940098779 methanesulfonic acid Drugs 0.000 description 1
 - ORIBUSCBDFDAIQ-GYYYEOQOSA-N methyl (6ar,9r)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylate Chemical compound C1=CC(C2[C@H](NC[C@@H](C2)C(=O)OC)C2)=C3C2=CNC3=C1 ORIBUSCBDFDAIQ-GYYYEOQOSA-N 0.000 description 1
 - 239000012046 mixed solvent Substances 0.000 description 1
 - 229910052757 nitrogen Inorganic materials 0.000 description 1
 - 125000004433 nitrogen atom Chemical group N* 0.000 description 1
 - 150000007530 organic bases Chemical class 0.000 description 1
 - 239000012074 organic phase Substances 0.000 description 1
 - 229930015720 peptide alkaloid Natural products 0.000 description 1
 - 229910000027 potassium carbonate Inorganic materials 0.000 description 1
 - 239000002244 precipitate Substances 0.000 description 1
 - 230000002315 pressor effect Effects 0.000 description 1
 - 108090000765 processed proteins & peptides Proteins 0.000 description 1
 - 238000000746 purification Methods 0.000 description 1
 - HYHBKLWDTGTBME-UHFFFAOYSA-N pyrazin-1-ium;chloride Chemical compound Cl.C1=CN=CC=N1 HYHBKLWDTGTBME-UHFFFAOYSA-N 0.000 description 1
 - 150000003254 radicals Chemical class 0.000 description 1
 - 239000011541 reaction mixture Substances 0.000 description 1
 - 229910052938 sodium sulfate Inorganic materials 0.000 description 1
 - 235000011152 sodium sulphate Nutrition 0.000 description 1
 - 239000002904 solvent Substances 0.000 description 1
 - 239000011877 solvent mixture Substances 0.000 description 1
 - 238000003756 stirring Methods 0.000 description 1
 - 239000000126 substance Substances 0.000 description 1
 - 150000003462 sulfoxides Chemical class 0.000 description 1
 - 239000012730 sustained-release form Substances 0.000 description 1
 - YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
 - 238000010792 warming Methods 0.000 description 1
 - 238000005406 washing Methods 0.000 description 1
 - 238000010626 work up procedure Methods 0.000 description 1
 
Classifications
- 
        
- C—CHEMISTRY; METALLURGY
 - C07—ORGANIC CHEMISTRY
 - C07D—HETEROCYCLIC COMPOUNDS
 - C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
 - C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P9/00—Drugs for disorders of the cardiovascular system
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P9/00—Drugs for disorders of the cardiovascular system
 - A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
 
 - 
        
- C—CHEMISTRY; METALLURGY
 - C07—ORGANIC CHEMISTRY
 - C07D—HETEROCYCLIC COMPOUNDS
 - C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
 - C07D519/02—Ergot alkaloids of the cyclic peptide type
 
 
Landscapes
- Organic Chemistry (AREA)
 - Chemical & Material Sciences (AREA)
 - Health & Medical Sciences (AREA)
 - Engineering & Computer Science (AREA)
 - Bioinformatics & Cheminformatics (AREA)
 - Cardiology (AREA)
 - Heart & Thoracic Surgery (AREA)
 - Medicinal Chemistry (AREA)
 - General Health & Medical Sciences (AREA)
 - Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
 - Life Sciences & Earth Sciences (AREA)
 - Chemical Kinetics & Catalysis (AREA)
 - General Chemical & Material Sciences (AREA)
 - Animal Behavior & Ethology (AREA)
 - Pharmacology & Pharmacy (AREA)
 - Public Health (AREA)
 - Veterinary Medicine (AREA)
 - Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
 - Peptides Or Proteins (AREA)
 - Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
 - Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
 - Nitrogen Condensed Heterocyclic Rings (AREA)
 - Pyridine Compounds (AREA)
 
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| CH1669873A CH587858A5 (enEXAMPLES) | 1973-11-28 | 1973-11-28 | 
Publications (1)
| Publication Number | Publication Date | 
|---|---|
| DE2454619A1 true DE2454619A1 (de) | 1975-06-05 | 
Family
ID=4419482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| DE19742454619 Withdrawn DE2454619A1 (de) | 1973-11-28 | 1974-11-18 | Verfahren zur herstellung neuer heterocyclischer verbindungen | 
Country Status (25)
| Country | Link | 
|---|---|
| US (1) | US4229451A (enEXAMPLES) | 
| JP (1) | JPS5919116B2 (enEXAMPLES) | 
| AT (1) | AT352911B (enEXAMPLES) | 
| BE (1) | BE822729A (enEXAMPLES) | 
| CA (1) | CA1034572A (enEXAMPLES) | 
| CH (1) | CH587858A5 (enEXAMPLES) | 
| CS (1) | CS176291B2 (enEXAMPLES) | 
| DD (1) | DD115119A5 (enEXAMPLES) | 
| DE (1) | DE2454619A1 (enEXAMPLES) | 
| DK (1) | DK143804C (enEXAMPLES) | 
| ES (1) | ES432288A1 (enEXAMPLES) | 
| FI (1) | FI59254C (enEXAMPLES) | 
| FR (2) | FR2252098B1 (enEXAMPLES) | 
| GB (2) | GB1496492A (enEXAMPLES) | 
| HK (1) | HK54080A (enEXAMPLES) | 
| HU (1) | HU168859B (enEXAMPLES) | 
| IE (1) | IE41767B1 (enEXAMPLES) | 
| IL (1) | IL46128A (enEXAMPLES) | 
| MY (1) | MY8100185A (enEXAMPLES) | 
| NL (1) | NL7415250A (enEXAMPLES) | 
| NO (1) | NO744175L (enEXAMPLES) | 
| PH (1) | PH13669A (enEXAMPLES) | 
| SE (2) | SE417319B (enEXAMPLES) | 
| SU (1) | SU516355A3 (enEXAMPLES) | 
| ZA (1) | ZA747603B (enEXAMPLES) | 
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| CH601321A5 (enEXAMPLES) * | 1975-01-06 | 1978-07-14 | Sandoz Ag | |
| CH619468A5 (enEXAMPLES) * | 1976-01-12 | 1980-09-30 | Sandoz Ag | |
| DE3020895A1 (de) * | 1979-06-12 | 1980-12-18 | Sandoz Ag | Ergopeptinderivate, verfahren zu deren herstellung sowie diese ergopeptinderivate enthaltende pharmazeutischen zusammensetzungen | 
| US5069911A (en) * | 1985-02-05 | 1991-12-03 | Sandoz Ltd. | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | 
| US7771746B2 (en) * | 1999-12-03 | 2010-08-10 | Polichem Sa | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof | 
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline | 
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline | 
| GB0505965D0 (en) * | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline | 
| US20070197576A1 (en) * | 2006-02-08 | 2007-08-23 | Resolution Chemicals Limited | Production of Cabergoline and Novel Polymorphic Form Thereof | 
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| DE1006425B (de) * | 1954-04-07 | 1957-04-18 | Sandoz Ag | Verfahren zur Herstellung der isomeren racemischen Dihydrolysergsaeuren und ihren Homologen | 
| DE2125588A1 (de) * | 1970-05-26 | 1971-12-09 | Sandoz Ag, Basel (Schweiz) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen | 
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US2619488A (en) * | 1952-11-25 | Method of preparing d | ||
| GB769260A (en) * | 1954-04-07 | 1957-03-06 | Sandoz Ltd | Process for the preparation of isomeric racemic dihydrolysergic acids and their homologues | 
| GB1011112A (en) * | 1961-05-10 | 1965-11-24 | Sandoz Ag | Improvements in or relating to ergot alkaloids | 
| CH469006A (de) * | 1965-07-07 | 1969-02-28 | Sandoz Ag | Verfahren zur Herstellung neuer synthetischer Alkaloide | 
| CH469735A (de) * | 1965-11-02 | 1969-03-15 | Sandoz Ag | Verfahren zur Herstellung heterocyclischer Verbindungen | 
| GB1298277A (en) * | 1969-04-18 | 1972-11-29 | Sandoz Ltd | Preparation of ergot peptide alkaloids | 
| CH601321A5 (enEXAMPLES) * | 1975-01-06 | 1978-07-14 | Sandoz Ag | |
| US4138565A (en) * | 1975-05-31 | 1979-02-06 | Sandoz Ltd. | Stable solutions and processes for their preparation | 
- 
        1973
        
- 1973-11-28 CH CH1669873A patent/CH587858A5/xx not_active IP Right Cessation
 
 - 
        1974
        
- 1974-11-18 DE DE19742454619 patent/DE2454619A1/de not_active Withdrawn
 - 1974-11-19 FI FI3345/74A patent/FI59254C/fi active
 - 1974-11-19 DK DK600374A patent/DK143804C/da not_active IP Right Cessation
 - 1974-11-20 NO NO744175A patent/NO744175L/no unknown
 - 1974-11-20 SE SE7414607A patent/SE417319B/xx unknown
 - 1974-11-22 NL NL7415250A patent/NL7415250A/xx not_active Application Discontinuation
 - 1974-11-25 GB GB23690/77A patent/GB1496492A/en not_active Expired
 - 1974-11-25 GB GB50914/74A patent/GB1496491A/en not_active Expired
 - 1974-11-26 HU HUSA2719A patent/HU168859B/hu unknown
 - 1974-11-26 IL IL46128A patent/IL46128A/en unknown
 - 1974-11-26 CS CS8081A patent/CS176291B2/cs unknown
 - 1974-11-26 DD DD182581A patent/DD115119A5/xx unknown
 - 1974-11-26 PH PH16563A patent/PH13669A/en unknown
 - 1974-11-26 AT AT945174A patent/AT352911B/de not_active IP Right Cessation
 - 1974-11-26 IE IE2432/74A patent/IE41767B1/en unknown
 - 1974-11-26 ES ES432288A patent/ES432288A1/es not_active Expired
 - 1974-11-27 JP JP49135657A patent/JPS5919116B2/ja not_active Expired
 - 1974-11-27 CA CA214,716A patent/CA1034572A/en not_active Expired
 - 1974-11-28 FR FR7439049A patent/FR2252098B1/fr not_active Expired
 - 1974-11-28 SU SU2082566A patent/SU516355A3/ru active
 - 1974-11-28 ZA ZA00747603A patent/ZA747603B/xx unknown
 - 1974-11-28 BE BE150971A patent/BE822729A/xx not_active IP Right Cessation
 
 - 
        1977
        
- 1977-01-31 FR FR7702636A patent/FR2334681A1/fr active Granted
 - 1977-09-16 SE SE7710418A patent/SE424869B/xx unknown
 
 - 
        1978
        
- 1978-06-29 US US05/920,480 patent/US4229451A/en not_active Expired - Lifetime
 
 - 
        1980
        
- 1980-09-25 HK HK540/80A patent/HK54080A/xx unknown
 
 - 
        1981
        
- 1981-12-30 MY MY185/81A patent/MY8100185A/xx unknown
 
 
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| DE1006425B (de) * | 1954-04-07 | 1957-04-18 | Sandoz Ag | Verfahren zur Herstellung der isomeren racemischen Dihydrolysergsaeuren und ihren Homologen | 
| DE2125588A1 (de) * | 1970-05-26 | 1971-12-09 | Sandoz Ag, Basel (Schweiz) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen | 
Non-Patent Citations (1)
| Title | 
|---|
| Chem.Abstr., 43, 1949, 4776a * | 
Also Published As
Similar Documents
| Publication | Publication Date | Title | 
|---|---|---|
| DE2228012B2 (de) | -Aminophenylacetamido] -penicülansäure und Verfahren zu seiner Herstellung | |
| DE2454619A1 (de) | Verfahren zur herstellung neuer heterocyclischer verbindungen | |
| EP0665228B1 (de) | Neue 3-Phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen enthaltende Arzneimittel | |
| DE3925496C2 (enEXAMPLES) | ||
| DE2225149C2 (de) | Oxofurylesterderivate der 6-(ą-Aminophenylacetamido)penicillansäure, Verfahren zu deren Herstellung und ihre Verwendung | |
| WO1996022989A1 (de) | NEUE 9H-PYRIDO[3,4-b]INDOL-DERIVATE | |
| DE2305514A1 (de) | Verfahren zur herstellung von lysergsaeureamiden und dihydrolysergsaeureamiden sowie lysergsaeureamide und dihydrolysergsaeureamide und ihre verwendung | |
| DE2557145B2 (de) | Tyrosinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2521709A1 (de) | Verfahren zur herstellung von neuen 2-arylamino-2-imidazolinderivaten | |
| CH610330A5 (en) | Process for the preparation of novel ergopeptins | |
| DE2525962A1 (de) | Neue heterocyclische verbindungen, ihre herstellung und verwendung | |
| DE1770227A1 (de) | Lysergsaeureamide und Verfahren zu deren Herstellung | |
| DE2221808C2 (de) | Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel | |
| DE2557792A1 (de) | Neue heterocyclische verbindungen, ihre herstellung und ihre verwendung | |
| DE3913756A1 (de) | 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung | |
| CH578565A5 (en) | N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity | |
| DE1695554C3 (de) | Verfahren zur Herstellung kondensierter Piperazinonderivate | |
| CH615182A5 (enEXAMPLES) | ||
| DE1795701B2 (de) | Alpha- substituierte benzylpenicillinsaeureester | |
| EP0219747B1 (de) | Neue 2-(2-Thienyl)-imidazo(4,5-c)pyridinderivate und deren Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate | |
| DE69310186T2 (de) | 1,2-dihydro-2-oxo-3-aminochinoxalin derivate, ihre verwendung als heilmittel | |
| CH602766A5 (en) | 10-Alpha-methoxy-di:hydro-beta-ergosine derivs. | |
| DE3303616A1 (de) | Mutterkornalkaloide, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische zubereitungen | |
| DE69629815T2 (de) | Verfahren zur herstellung von penicilling-phenylester | |
| DE2404924A1 (de) | Ergolinderivate | 
Legal Events
| Date | Code | Title | Description | 
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8139 | Disposal/non-payment of the annual fee |